Loading company…
Oncgnostics develops molecular diagnostic tests for cancer, including cervical cancer.
Oncgnostics develops molecular diagnostic tests for early cancer detection. Its GynTect® test for cervical cancer has been available since 2015, and the company is developing tests for head and neck tumors and ovarian cancer. Founded in 2012, it is based in Jena, Germany. In September 2023, it raised EUR 0.600 mn in a Seed round led by High-Tech Gründerfonds to expand test distribution into ASEAN countries.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in